噬菌體療法市場規模、佔有率、成長分析（按產品、類型、適應症、最終用戶和地區）- 2025 年至 2032 年產業預測

2023 年全球噬菌體療法市場規模為 2,980 萬美元，預計將從 2024 年的 3,499 萬美元成長到 2032 年的 1.2625 億美元，預測期內（2025-2032 年）的複合年成長率為 17.4%。

為了應對日益嚴重的抗生素抗藥性威脅，全球噬菌體治療市場正在迅速發展，這是一個迫切的公共衛生問題。推動成長的因素包括多重抗藥性感染疾病的增加、對替代抗菌療法的投資增加以及公共和私營部門加強研發力度。噬菌體療法因其對病原體的高度特異性、對正常微生物群的保存以及最小的副作用而成為一種有吸引力的治療選擇。政府舉措正在進一步刺激創新，尤其是在北美和歐洲。然而，監管的不確定性、有限的臨床證據和後勤挑戰繼續阻礙其廣泛採用。然而，基因組定序和個人化醫療的進步可能會克服這些障礙，預示著噬菌體療法在對抗超級細菌和重塑感染疾病治療方面有著光明的前景。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術進步
• 案例研究
• 專利分析

噬菌體治療市場規模（按產品和複合年成長率） (2025-2032)

• 市場概覽
• 大腸桿菌
• 金黃色葡萄球菌
• 沙門氏菌
• 銅綠假單胞菌
• 其他

噬菌體治療市場規模（按類型及複合年成長率） (2025-2032)

• 市場概覽
• 雙股DNA噬菌體
• SsDNA噬菌體
• SsRNA噬菌體
• 其他

噬菌體療法市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概覽
• 尿道感染
• 慢性中耳炎
• 慢性潰瘍性大腸炎
• 骨感染疾病
• 傷口/皮膚感染疾病
• 囊腫纖維化
• 其他適應症

噬菌體治療市場規模（依最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院和診所
• 研究和學術機構
• 其他

噬菌體治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Armata Pharmaceuticals（United States）
• BiomX Inc.（Israel）
• Intralytix（United States）
• Locus Biosciences（United States）
• Amplify Biosciences（United States）
• EnBiotix（United States）
• PhagoMed Biopharma（Austria）
• Transgene SA（France）
• Imugene Ltd（Australia）
• Evotec SE（Germany）
• Novolytics（United Kingdom）
• GangaGen Biotechnologies（India）
• Pherecydes Pharma（France）
• Eligo Bioscience（France）
• Micreos（Netherlands）
• ContraFect Corporation（United States）
• Phagomed Biopharma GmbH（Austria）
• PhagePro Inc.（United States）
• TechnoPhage（Portugal）
• Intralytix, Inc.（United States）

結論和建議

Global Phage Therapy Market size was valued at USD 29.8 million in 2023 and is poised to grow from USD 34.99 million in 2024 to USD 126.25 million by 2032, growing at a CAGR of 17.4% during the forecast period (2025-2032).

The global Phage Therapy Market is rapidly gaining traction in response to the escalating threat of antibiotic resistance, a pressing public health issue. Growth drivers include the rise of multidrug-resistant infections, increased investments in alternative antimicrobial therapies, and enhanced R&D efforts from both public and private sectors. Phage therapy offers high specificity against pathogens, maintains the normal microbiome, and has minimal side effects, making it an attractive treatment option. Government initiatives, particularly in North America and Europe, further stimulate innovation. However, regulatory uncertainties, limited clinical evidence, and logistical challenges hinder widespread adoption. Yet, advancements in genome sequencing and personalized medicine may overcome these barriers, signaling a promising future for phage therapy in combating superbugs and reshaping anti-infective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Phage Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Phage Therapy Market Segments Analysis

Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Phage Therapy Market

The global phage therapy market is primarily driven by the rising threat of antimicrobial resistance (AMR), which occurs when bacteria evolve to resist antibiotics, complicating the treatment of infections. The misuse and overprescription of these medications have led to a significant rise in AMR cases, resulting in increased mortality rates, the spread of diseases, and escalating healthcare expenses. The World Health Organization projects that by 2050, AMR could cause up to 10 million deaths annually. As such, there is a growing need for alternative treatments like phage therapy to address these challenges and manage the increasing prevalence of chronic infections.

Restraints in the Global Phage Therapy Market

One of the primary obstacles facing the global phage therapy market is the insufficient clinical evidence supporting its efficacy and safety. Currently, most available research is limited to small-scale studies or compassionate use cases, which often lack the rigorous testing found in large randomized controlled trials. This deficiency undermines the confidence of healthcare professionals and regulatory bodies in phage treatments. Consequently, this skepticism hampers efforts to gain regulatory approval, establish acceptance among practitioners, and scale the therapy for broader use. As a result, the commercial introduction of phage therapy and its integration into standard treatment protocols are significantly hindered.

Market Trends of the Global Phage Therapy Market

The Global Phage Therapy market is witnessing a significant trend towards the integration of artificial intelligence and bioinformatics, revolutionizing treatment specificity and efficacy. As developers increasingly utilize AI-assisted phage-host prediction programs and automated screening platforms, the acceleration of phage selection and development is becoming more efficient and cost-effective. This technological innovation not only reduces development timelines but also enhances therapeutic precision, making phage therapy a promising component of personalized medicine. As a result, the market is poised for substantial growth, reflecting the rising demand for targeted treatments in the face of antibiotic resistance and complex infectious diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Studies
• Patent Analysis

Global Phage Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Escherichia coli
• Staphylococcus aureus
• Salmonella
• Pseudomonas aeruginosa
• Others

Global Phage Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• Others

Global Phage Therapy Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Urinary Tract Infections
• Chronic Otitis
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications

Global Phage Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital & Clinics
• Research & Academic Institutes
• Others

Global Phage Therapy Market Size & CAGR (2025-2032)

• North America (Product, Type, Disease Indication, End User)
  • US
  • Canada
• Europe (Product, Type, Disease Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Disease Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Disease Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Disease Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Armata Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomX Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amplify Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EnBiotix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagoMed Biopharma (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novolytics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GangaGen Biotechnologies (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ContraFect Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagomed Biopharma GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagePro Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations